Keyword Connections

bortezomib

Journals

6

1 PloS one

2 PLoS computational biology

3 journal of nursing care quality

4 The Journal of nervous and mental disease

5 hematological oncology

6 Clinical and experimental rheumatology

Research Groups

0

No Research Group Connected

Bibliographies

24

1 evodiamine selectively inhibits multiple myeloma cell growth by triggering activation of intrinsic apoptosis pathway

2 celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myeloma

3 bortezomib modulates chit1 and ykl40 in monocyte-derived osteoclast and in myeloma cells

4 partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy

5 Dual Mutations in and Confer High-Level Resistance to Bortezomib and Linezolid by Both Reducing Drug Intake and Increasing Efflux in .

6 The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm.

7 Efficacy and safety of a bortezomib and reduced-intensity cytarabine-based protocol, TMC ALLR1, for relapsed childhood ALL in India

8 A comparison of response in the presence or absence of a delay in induction therapy with bortezomib, lenalidomide, and dexamethasone.

9 Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib.

10 [Comparison analysis of outcomes in primary light chain amyloidosis patients treated by auto peripheral blood stem cell transplantation or bortezomib plus dexamethasone].

11 Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

12 Bortezomib in patients with renal impairment.

13 Bortezomib: a new therapeutic option for POEMS syndrome.

14 Ursodeoxycholic acid inhibits glioblastoma progression via endoplasmic reticulum stress related apoptosis and synergizes with the proteasome inhibitor bortezomib.

15 (Bortezomib plus lenalidomide/thalidomide)- vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials

16 Successful treatment of lymph node extramedullary plasmacytoma with bortezomib

17 Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib

18 changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study

19 inhibition of p-selectin and psgl-1 using humanized monoclonal antibodies increases the sensitivity of multiple myeloma cells to bortezomib

20 proteasome inhibitor bortezomib suppresses nuclear factor-kappa b activation and ameliorates eye inflammation in experimental autoimmune uveitis

21 management of multiple myeloma and usage of bortezomib: perspective from india and ukraine

22 Real-world effectiveness and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma in Slovakia.

23 Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

24 Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UK